Status:
RECRUITING
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Lead Sponsor:
AstraZeneca
Conditions:
Endometrial Cancer
Eligibility:
All Genders
Brief Summary
Objectives of this study are to assess the safety and effectiveness of Durvalumab with or without Olaparib (hereinafter "the study drug") in a real world setting in patients who are prescribed with th...
Detailed Description
Primary Objective: To assess the safety of the study drug in patients prescribed with the study drug under the approved indication(s) in Korea Secondary Objective: To assess effectiveness of the stud...
Eligibility Criteria
Inclusion
- Patients eligible for the study drug according to the approved label in Korea
- Provision of a signed and dated written informed consent by the patient or their legally acceptable representative
Exclusion
- Participation in any concurrent interventional trials during the period of the study drug treatment
- Other off-label indications according to the approved label in Korea
Key Trial Info
Start Date :
September 19 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 29 2029
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06995833
Start Date
September 19 2025
End Date
June 29 2029
Last Update
December 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Seoul, South Korea